Guru Ownership Trend
Guru Analysis for Syndax Pharmaceuticals, Inc. (SNDX)
Syndax Pharmaceuticals, Inc. (SNDX), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q1 2026, a total of 4 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $70.45 M.
Top institutional holders include Steven Cohen and Cliff Asness.
Institutional sentiment is currently Bearish. This is evidenced by a $66.98 M net outflow during the quarter.
Recent activity highlights Paul Tudor Jones who increased their stake by 45.6%. Conversely, Steven Cohen reduced exposure by 59.3%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q1 2026)
Guru Consensus (Q1 2026)
FAQs for Syndax Pharmaceuticals, Inc. (SNDX)
Major holders include Steven Cohen ($46.38 M), Cliff Asness ($22.9 M), Renaissance Technologies (RenTech) ($11.64 M). According to the latest reported data, 4 tracked investment managers collectively hold approximately 3.53 M shares.
According to the latest 13F reporting period, sentiment appears Bearish (Net Selling). There was a net outflow of $66.98 M, with 2 managers increasing positions and 3 managers reducing holdings.
During the most recent reporting period, 2 managers trimmed their positions, while 1 fully exited SNDX. The total reported sell value was $68.76 M.
Yes, 0 managers opened new positions in SNDX, and 2 increased their existing holdings. The total reported buy value was $1.77 M.